If her weakness and numbness are a new, typical focal neurologic episode after a stable interval, not a fever- or infection-related pseudo-relapse and not better explained by another cause, the five-day duration supports a clinical relapse. New T2 lesions on comparison with prior imaging—and a gadolinium-enhancing lesion—also support radiological activity. The useful classification is active on both axes, not necessarily severe, and not automatically worsening.
The clinical details still matter. A five-day symptom duration clears the usual 24-hour threshold, but duration alone does not establish a relapse. Confirm the relevant baseline, the timing of any prior episode, and whether the symptoms fit a new inflammatory CNS event.
Keep the two evidence channels separate
| Evidence | What it supports | What it does not establish by itself |
|---|---|---|
| New or worsening typical neurologic symptoms, lasting at least 24 hours | Clinical relapse, if competing explanations are excluded and the episode is distinct from the prior one | That every MRI lesion caused symptoms |
| New or unequivocally enlarging T2 lesions, or gadolinium-enhancing lesions, compared with prior MRI | Radiological disease activity in the assessed interval | A symptomatic relapse, its severity, or the number of clinical attacks |
| Both clinical and MRI findings | Activity supported on both clinical and radiological grounds | Two separate attacks, disability progression, or a treatment decision without further context |
These are distinct ways to observe inflammatory activity; they are not necessarily separate biological events. One symptomatic episode may coincide with MRI changes, while MRI can also reveal activity that the patient did not notice.
“Active” is a time-bounded description. State the interval represented by the symptoms and scans; do not imply that activity has continued indefinitely. The vignette also does not establish her underlying MS course or whether disability has worsened over time, so neither should be inferred from this episode alone.
Read the comparison, not just the scan
A T2 lesion can remain visible after the acute inflammatory phase. Its presence on today’s scan does not make it newly active. Radiological activity depends on comparison: is it genuinely new or unequivocally larger than on an earlier, technically comparable study?
Gadolinium enhancement reflects temporary blood–brain barrier disruption associated with active lesion inflammation. It can strengthen the evidence for recent inflammatory activity, but enhancement is not required for a new T2 lesion to count as radiological activity. Nor does enhancement prove that a lesion caused the patient’s symptoms: enhancing lesions may be clinically silent.
Serial MRI interpretation therefore depends on having an appropriate reference scan and comparable imaging. If the prior images or relevant sequences are unavailable, be cautious about calling a lesion new. In this case, the supplied comparison establishes new T2 lesions and an enhancing lesion, so the scan supports radiological activity during the observed interval.
Make the clinical label earn its place
Start with the patient’s usual neurologic and functional baseline. Clarify what changed—such as strength, sensation, walking, or hand use—and when. Ask whether the symptoms are new or a temporary return of old deficits, whether there was a period of stability, and whether fever, infection, or another explanation could account for them. Document the examination findings that corroborate the reported change.
A distinct relapse is generally separated from the onset of the previous episode by at least 30 days. Fever or infection may trigger temporary worsening of old deficits, but does not automatically exclude a concurrent relapse; assess whether there is a distinct new inflammatory event and consider other explanations. If the symptom pattern is atypical, the examination is not supportive, or the necessary timeline is missing, describe the evidence conditionally rather than letting the MRI substitute for the clinical assessment.
For this case, the defensible formulation is: assuming the symptoms are typical, distinct from a recent prior episode, and not better explained by a pseudo-relapse or another cause, she has both clinical and radiological activity in the assessed interval. If those clinical assumptions are not established, the scan still supports radiological activity, while the clinical event remains a suspected relapse.
Activity is not the same as severity or progression
“Active” answers whether there is evidence of new inflammatory disease activity. It does not grade how disabling the episode is, how much function she has lost, or whether she is accumulating disability. Those require their own assessment over time. In particular, disability worsening after a relapse and progression independent of relapses are not interchangeable descriptions.
The activity label also does not prescribe treatment. Whether to treat an acute symptomatic relapse depends on its functional impact and the individual clinical context. Whether MRI activity should change disease-modifying therapy requires review of factors such as treatment exposure and timing, adherence, and the scan interval—not an automatic switch based on one word or lesion count.
Practical takeaways
- Classify clinical relapse and MRI activity separately before combining them.
- Five days exceeds the usual duration threshold, but a relapse label still requires a compatible episode, relevant timeline, and no better explanation.
- New or enlarging T2 lesions count through comparison with prior imaging; enhancement supports recent activity but is not required for every active lesion.
- Activity does not, by itself, mean severe relapse, disability progression, or treatment failure.
